D&I webinaari – Disputes for Breakfast

D&I Event

Event date

1 Mar


Dittmar & Indrenius > Insight > D&I webinaari – Disputes for Breakfast

Intellectual Property Fights -webinaarisarjamme kolmannessa osassa pureudumme käytännönläheisesti työntekijöiden kanssa syntyvien IPR-riitojen ennaltaehkäisemiseen, niihin varautumiseen ja jo kehkeytyneiden riitojen anatomiaan, erityisesti tekijänoikeudet ja työsuhdekeksinnöt huomioiden:

  • Miten strategisesti ennaltaehkäistään IPR-liitännäisten riitojen syntymistä työntekijöiden kanssa?
  • Miten työntekijän kanssa laadittavin sopimuksin voidaan ennaltaehkäistä ja varautua IPR-riitoihin? Missä määrin aihe tulisi huomioida kolmansien kanssa tehtävissä sopimuksissa?
  • Mistä riidat kokemuksemme mukaan kehkeytyvät ja miten tällöin tulisi toimia?

Puhujina ovat D&I:n Senior Attorney, Head of Intellectual Property Iiris Kivikari, Senior Associate Charlotta Bonsdorff, Senior Associate Laura Parkkisenniemi sekä Associate Camilla Stelmacher .

Tervetuloa mukaan!

Jos et ole saanut kutsua tilaisuuteen ja haluaisit osallistua, voit olla yhteydessä: [email protected]

More by the same author

The EU’s Pharmaceutical Legislation Reform

The European Union’s imminent pharmaceutical legislation reform aims to modernise its regulatory framework, focusing on improving patient access to medicines, fostering innovation, and minimising environmental impact. This strategic overhaul, set against a backdrop of industry challenges and evolving IP rights, underscores the EU’s commitment to balancing innovation with accessibility and sustainability in healthcare.

Ready or Not, Here Comes the AI Act!

D&I’s summary of the changes coming your way The European Parliament has approved the Artificial Intelligence Act on 13 March 2024. The AI Act is a huge step forward in creating a legal framework for AI technology throughout the European Union. It brings about substantial new obligations for both the developers and users of artificial intelligence (or, using the terminology of the Act itself, the providers, importers, deployers, authorised representatives and other parties listed in the Act). However, although the categorisation does cut a few corners, the AI Act can be seen as a type of “product safety” legislation. As such, it leaves a wide range of topics to be dealt with in other EU and/or national laws, or by the parties involved in a specific transaction.

Commission proposes extension of IVDR transition periods for legacy products

The European Commission has on 23 January 2024 announced a proposal for an extension to the transition period for the forthcoming In Vitro Diagnostic Medical Devices Regulation (IVDR). The aim is to ensure patient care by improving the availability of these essential healthcare products. In addition, the Commission also proposes measures to enable and accelerate a gradual roll out of EUDAMED, a database that will contain information about all medical devices and in vitro diagnostics (IVDs) placed on the EU market. The mandatory use of finalised parts of EUDAMED will support all key players in the implementation of the regulatory framework and enhance transparency for the public.

Latest insights

Are Finnish Lawyers the Happiest in the World?

Article / 4 Apr 2024
Reading time 2 minutes

Implementing the Data Act without Clashing with the GDPR?

Article / 4 Apr 2024